Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$6.83 USD
+0.10 (1.49%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.84 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FULC 6.83 +0.10(1.49%)
Will FULC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FULC
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
New Strong Buy Stocks for November 12th
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
Pacira's Exparel Receives Permanent New Product-Specific J-Code
Other News for FULC
RBC Capital Maintains Rating and Raises Price Target for Fulcrum Therapeutics (FULC) | FULC ...
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug
FULC Stock: Fulcrum Therapeutics Upgraded to Buy by HC Wainwright | FULC Stock News
Fulcrum Therapeutics (FULC) Receives Upgrade to Buy with Price Target Set at $12